NCT06341543View on ClinicalTrials.gov

Quantiferon CMV to Identify Treatment Need for Asymptomatic CMV Infection After Solid Organ Transplant (QUANTIFOT)

NARecruitingINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

September 24, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Cytomegalovirus InfectionsHeart TransplantationKidney TransplantationLung TransplantationLiver Transplantation
Interventions
DIAGNOSTIC_TEST

Quantiferon CMV (assay that determine the presence of CMV-specific T lymphocytes).

The QF-CMV will be performed in all participants.

OTHER

Communication of the result of the QF-CMV to the clinician in charge

"The result of the CMV-QF will be communicated to the clinician in charge only for the patients randomised in the group communication of the QF-CMV result to the clinician in charge."

Trial Locations (1)

38043

RECRUITING

CHU Grenoble Alpes, Grenoble

All Listed Sponsors
lead

University Hospital, Grenoble

OTHER

NCT06341543 - Quantiferon CMV to Identify Treatment Need for Asymptomatic CMV Infection After Solid Organ Transplant (QUANTIFOT) | Biotech Hunter | Biotech Hunter